Literature DB >> 8157467

Methodological issues in antiemetic studies.

M Aapro1.   

Abstract

Mesh:

Substances:

Year:  1993        PMID: 8157467     DOI: 10.1007/bf00874423

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  52 in total

Review 1.  How should nausea be assessed in patients receiving chemotherapy?

Authors:  S B Kaye
Journal:  Cancer Treat Rev       Date:  1991-06       Impact factor: 12.111

2.  A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.

Authors:  I E Smith
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

3.  Myths of antiemetic administration.

Authors:  C A Peters
Journal:  Cancer Nurs       Date:  1989-04       Impact factor: 2.592

4.  Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.

Authors:  B Chevallier
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.

Authors:  M V Tabona
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.

Authors:  M Soukop
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

7.  High-dose dexamethasone for prevention of cis-platin-induced vomiting.

Authors:  M S Aapro; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy.

Authors:  D R Nerenz; H Leventhal; D V Easterling; R R Love
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

9.  GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.

Authors:  P J Hesketh; W K Murphy; E P Lester; D R Gandara; A Khojasteh; E Tapazoglou; G P Sartiano; D R White; K Werner; J M Chubb
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

10.  The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

Authors:  M H Bronchud; A Howell; D Crowther; P Hopwood; L Souza; T M Dexter
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

View more
  4 in total

Review 1.  Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.

Authors:  Steven M Grunberg; David Osoba; Paul J Hesketh; Richard J Gralla; Sussanne Borjeson; Bernardo L Rapoport; Andreas du Bois; Maurizio Tonato
Journal:  Support Care Cancer       Date:  2004-12-14       Impact factor: 3.603

Review 2.  A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting.

Authors:  Kristopher Dennis; Rehana Jamani; Clare McGrath; Leila Makhani; Henry Lam; Patrick Bauer; Carlo De Angelis; Natalie Coburn; C Shun Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2017-03-31       Impact factor: 3.603

Review 3.  Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.

Authors:  Cesare Gridelli; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-03-04       Impact factor: 3.603

Review 4.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.